Sarepta Therapeutics (SRPT) Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Sarepta Therapeutics (SRPT) Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Sarepta Therapeutics (SRPT) Tops Q1 EPS by 23c, Revenues Beat

May 5, 2021 4:39 PM EDT

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.54), $0.23 better than the analyst estimate of ($1.77). Revenue for the quarter came in at $146.93 million versus the consensus estimate of $143.33 million.

In the first quarter, we obtained FDA approval for and launched our third RNA therapy for Duchenne, AMONDYS 45 (casimersen). The first AMONDYS 45 patient was treated within the first week of approval. Serving the community with EXONDYS 51, VYONDYS 53, and AMONDYS 45, we achieved net product revenue of $124.9 million, a 24%... More

Sarepta Therapeutics (SRPT) Data 'Positive but Some Questions Remain' - Mizuho

May 3, 2021 1:43 PM EDT

Mizuho Securities analyst Difei Yang reiterated a Buy rating and $160.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company presented new data from its next-generation exon skipping PPMO at the 30mg dose.

Yang commented, "The data was in line with our "base case"... More

Needham & Company Reiterates Buy Rating on Sarepta Therapeutics (SRPT) on Positive 5051 Update

May 3, 2021 11:58 AM EDT

Needham & Company analyst Chad Messer reiterated a Buy rating and $166.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company reported updated clinical results from its multi-dose ascending study of SRP-5051, its exon 51 skipping PPMO in Duchenne Muscular Dystrophy (DMD).

Messer commented,... More